PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Authors
Keywords
-
Journal
Frontiers in Physiology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-11-16
DOI
10.3389/fphys.2020.595819
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Evolocumab in Patients With Familial Hypercholesterolemia
- (2020) Raul D. Santos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES
- (2020) Shaun G. Goodman et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
- (2020) Peter Sever et al. European Journal of Preventive Cardiology
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome
- (2020) Gregory G. Schwartz et al. CIRCULATION
- The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- (2020) Nicholas A. Marston et al. CIRCULATION
- Cognition After Lowering LDL-Cholesterol With Evolocumab
- (2020) Baris Gencer et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes
- (2020) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
- (2020) Robert P. Giugliano et al. STROKE
- Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction
- (2020) Stephen D. Wiviott et al. JAMA Cardiology
- Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction
- (2020) Baris Gencer et al. JAMA Cardiology
- New Pharmacological Approaches to Target PCSK9
- (2020) Alberico L. Catapano et al. Current Atherosclerosis Reports
- Statin intolerance: myths and facts
- (2020) Ulrich Laufs et al. EUROPEAN HEART JOURNAL
- Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
- (2020) Julius L. Katzmann et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia
- (2020) Dirk J. Blom et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
- (2020) Prakash Deedwania et al. JAMA Cardiology
- Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia
- (2020) Raul D. Santos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness of Alirocumab
- (2019) Dhruv S. Kazi et al. ANNALS OF INTERNAL MEDICINE
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study
- (2019) Tim Hollstein et al. VASCULAR PHARMACOLOGY
- Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial
- (2019) J. Wouter Jukema et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
- (2019) Harvey D White et al. EUROPEAN HEART JOURNAL
- Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
- (2019) Maria Pia Adorni et al. Frontiers in Aging Neuroscience
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes
- (2019) Philippe Gabriel Steg et al. CIRCULATION
- Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
- (2019) David M. Charytan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort
- (2019) Alexander Dressel et al. VASCULAR PHARMACOLOGY
- Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
- (2019) Susanne Schuster et al. Scientific Reports
- New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease
- (2019) Julius L. Katzmann et al. Current Cardiology Reports
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
- (2019) Shaun G. Goodman et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS)
- (2019) Konstantinos C. Koskinas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial
- (2019) Nicholas A. Marston et al. CIRCULATION
- Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial
- (2019) Amy Damask et al. CIRCULATION
- Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
- (2019) Peter R Sinnaeve et al. EUROPEAN HEART JOURNAL
- Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
- (2019) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
- (2019) J. Wouter Jukema et al. CIRCULATION
- Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER
- (2018) Marc S. Sabatine et al. CIRCULATION
- Inflammatory and Cholesterol Risk in the FOURIER Trial
- (2018) Erin A. Bohula et al. CIRCULATION
- Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
- (2018) Merel L. Hartgers et al. Journal of Clinical Lipidology
- The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors
- (2018) Eleni Theocharidou et al. CURRENT PHARMACEUTICAL DESIGN
- The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption
- (2018) Günther Silbernagel et al. JOURNAL OF LIPID RESEARCH
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab Reduces Fatal and Nonfatal Cardiovascular Events
- (2018) Michael Szarek et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 inhibitors: clinical evidence and implementation
- (2018) Marc S. Sabatine Nature Reviews Cardiology
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab
- (2018) Arman Qamar et al. JAMA Cardiology
- Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
- (2017) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach
- (2017) Nina Scherer et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
- (2017) Frederick J Raal et al. Lancet Diabetes & Endocrinology
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin
- (2017) Robert P. Giugliano et al. JAMA Cardiology
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
- (2016) Eli M. Roth et al. ATHEROSCLEROSIS
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)
- (2016) Sandy Elbitar et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role
- (2016) Frederick J. Raal et al. JOURNAL OF LIPID RESEARCH
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
- (2015) Dean J. Kereiakes et al. AMERICAN HEART JOURNAL
- Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
- (2015) Rainer Schulz et al. BASIC RESEARCH IN CARDIOLOGY
- ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
- (2015) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
- (2015) Erik S. Stroes et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial
- (2014) Eli M. Roth et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
- (2014) Jennifer G. Robinson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
- (2013) Daniel Urban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
- (2013) Ron T Gansevoort et al. LANCET
- Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous Thrombosis
- (2012) Pia R. Kamstrup et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Apolipoprotein(a) Genetic Sequence Variants Associated With Systemic Atherosclerosis and Coronary Atherosclerotic Burden But Not With Venous Thromboembolism
- (2012) Anna Helgadottir et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipoprotein(a), polymorphisms in theLPAgene, and incident venous thromboembolism among 21 483 women
- (2012) J. S. DANIK et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started